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CELLS in mitosis, or preparing for mitosis, have proved susceptible to a wide
range of compounds. Encouragement to continued efforts to find more effective
anti-mitotics has come from the ability of existing agents to achieve the frequent
cure of some patients with gestational choriocarcinoma, the less regular cure of
patients with some other uncommon solid tumours, and a high rate of temporary
remission in many leukaemias. Except for thisrelativelysmallrangeofneoplasms,
aniti-mitotics have so far been found to have only limited value. It is recognised
that to be more effective they require an additional basis for selective action against
tumour cells (Haddow, 1963) but in general their failure has been attributed to the
development ofresistance operating through the classical mechanisms of variation
and selection (Law, 1956; Potter, 1958; Klein, 1961; Welch, 1965).
The general feasibility ofcontrolling tumour growth and ofeliminating tumours
with anti-mitotic agents, in the absence of classical drug resistance, has received
little attention and it is the purpose of this paper to examine this question.
Tumour growth has been studied in terms ofchange ofvolume as a function oftime
and in terms of cell proliferation kinetics. The less studied inter-relationship of
these two functions is central to our understanding of tumour growth but it is
complicated by two factors. One is that some tumour cells die and the other is
that tumours do not usually consist exclusively of fertile or proliferative tumour
cells (Table I). A consideration of this inter-relationship precedes the present
analysis of anti-mitotic action.
TABLE I.-Tumour Constituents
Tumour cells 1. Living cells WITH capacity to dividle
2. Living cells WITHOUT capacity to divi(le
3. Dead cells
Host cells 1. Monocytes
2. Phagocytes
3. Fibroblasts
Other matter . 1. Vessels
2. Stroma (non-cellular components)
3. Haemorrhage
4. Necrotic debris
Tumour volume
Estimates of volume doubling time for various human primary and secondary
masses have ranged from 4 to 745 days (Collins et al., 1956; Schwartz, 1961;
Collins, 1962; Welin et al., 1963; Garland et al., 1963; Spratt and Spratt, 1964;
Breur, 1966). Tumours with volume doubling times of less than 25 days are
generally regarded as fast growing and are somewhat exceptional. It is alsoTUMOUR GROWTH AND ANTI-MITOTIC ACTION
commonly observed that the volume of tumours increases exponentially for a
period oftheir growth, but that whatever index is used to express volume the rate
of increase eventually tends to decline (Mayneord, 1932; Shrek, 1936; Haddow,
1938; Patt and Blackford, 1954; Mendelsohn, 1963).
Cell proliferation
Potential growth.-The potential growth rate ofa cell population can be defined
as the rate at which its numbers would increase ifall the cells were to survive and if
the fraction in mitosis were to remain constant. A hypothetical population of
fully synchronised cells proliferating by mitosis or binary fission would increase by
a series oftwo-fold steps and the number of cells present at any time (N) could be
calculated simply from the formula N = 2x where x is the number of divisions
which had taken place.
In the fully asynchronous state, ifthe interval between successive doublings of
the number of cells is constant, growth is exponential and the growth rate at any
instant can be expressedasdN/dt. Also,whengrowthisexponential,dN/dt KN,
where t = time, and K is a constant.
It has been known for many years that bacteria in favourable growth condi-
tions in liquid media tend to increase in this fashion. Collins et al. (1956) presented
data for a tumour cell population with a mean cell diameter of 10 1%, making the
assumption that all cells survived. After 20 successive doublings the tumour
would reach a diameter of 1 cu. mm., after 30 doublings it would reach 1 cu. cm.
and after 40 doublings it would consist ofabout 1012 cells and weigh 1 kg. With a
total body population of the order of 5 x 1013 cells, the significance of a few
" doublings " at the top end of this scale is apparent. It is also clear that the
clinically recognised part of such a tumour's history would be the last quarter of
its whole time scale. With this scale the only variable in the rate of increase of
the number of cells is the interval between successive doublings.
In vitro isotopic labelling of Burkitt's lymphoma cells indicated that many of
them had potential doubling times of less than 24 hours (Cooper et al., 1966).
In vivo labelling of leukaemic blast cells gave values of 50-80 hours (Killmann
et al., 1963; Mauer, 1964), stomach carcinoma 66 hours, colon carcinoma 75 hours
(Baserga et al., 1962), bronchial carcinoma 75 hours (Titus and Shorter, 1965), liver
carcinoma 10 days, ovarian carcinoma 45 days (Baserga et al., 1962) and breast
carcinoma 90 days (Johnson et al., 1960).
It is now generally accepted that tumour cells do not generally proliferate more
rapidly than certain normal tissues (Baserga, 1965). Human polychromatophil
normoblasts were found to have a cell cycle time (average interval between succes-
sive mitoses) of 15-18 hours (Patt andMaloney, 1959) andfor humanrectal mucosal
cells an average time of 25 hours was reported (Cole and McKalen, 1961).
Cell losses.-Not all cells survive to undergo successful mitosis and it is neces-
sary to distinguish between loss of proliferating capacity and loss of the physical
space occupied by a cell. A cell can be regarded as " lost " from a fertile popula-
tion when it has irreversibly lost its potential to undergo successful mitosis. In a
steady state compartment, an average of one of each pair of daughter cells result-
ing from mitosis is lost without dividing.
Cell losses from tumours may be external or internal to the tumour mass.
External losses occur by desquamation from epithelial surfaces or into the blood
stream, by lymphatic drainage, or by isolated infiltration of adjacent tissues.
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Whether these constitute losses from the local tumour only or from the whole
tumour cell population, clearly depends on the ultimate fate of the cells, but
obviously not all cells lost externally continue to proliferate. Tumour cell loss
may also result from host-tumour interaction at their mutual interface. Within
the tumour mass itself, cell death may result from unfavourable metabolic condi-
tions and from the functional inadequacies of aneuploidy. Burton (1966) has
theorized that for each tumour there is a critical radius where central necrosis
starts to appear and, at about 5 or 6 times this value, the cortex ofdividing cells
becomes constant at 58% of the critical tumour radius. A further source of loss
from the fertile population is the maturation and differentiation of cells to non-
proliferative forms, but losses of this type are difficult to identify unless accom-
panied by characteristic morphological changes.
Evidence of a high rate of spontaneous cell loss has been reported for Burkitt
lymphoma (Cooper et al., 1966) and for some leukaemias (Killmann et al., 1963;
Mauer, 1964). Direct quantitative evidence ofa high rate ofspontaneous cell loss
in gestational choriocarcinoma has not yet been obtained, but it may be inferred
from qualitative evidence (Bagshawe, 1968). There is extensive desquamation of
choriocarcinoma cells into the blood, the tumour masses are mostly necrotic except
for a thin peripheral skin of tumour cells, there is differentiation to a non-
replicating syncytium and the possibility that an immunological reaction to this
allogeneic tumour also contributes to cell loss.
There have been some recent attempts to quantitate spontaneous cell losses in
humantumours from estimatesofpotentialgrowth rates ofcells andobservedrates
of change of tumour volume. Iversen (1967) concluded that between 95-99% of
cells added by mitosis were lost spontaneously and Steel (1967) concluded that
more than 50% of the added cells were lost. Spontaneous cell losses represent
the difference between the potential and the actual growth rates of the cells;
dissociation of the rate of change of tumour volume from the actual growth rate
ofthe cells, would, ifanything, be likely to cause under-estimation of cell losses by
the methods used by these authors.
Actual growth.-The actual growth rate of a tumour cell population equals the
potential growth rate minusthe rate ofcell loss. It is the rate atwhichfertile cells
are increasing ordecreasing innumber. Taking celllossesinto account meansthat
each cell division gives rise, in effect, not to 2 daughter cells, but to "q " daughter
cells where 2 > q > 1 ifthepopulation is increasing, 1 = qifit is in a steady state,
and 1 > q if the population is decreasing. A proliferating population (N) which
has gone through a series of x synchronised divisions but has suffered a constant
rate of loss could thus be represented by N = qx. Any actual growth rate could
result from an infinite range of combinations of different potential growth rates
and spontaneous loss rates.
Techniques for the study of the actual growth rate of human tumour cell
populations are lacking although the rate of change of gonadotrophin production
bytrophoblastic tumoursprovides a useful approximationtothisindex (Bagshawe,
1968).
Relationship between tumour volume and cellproliferation
If there were no losses from a tumour cell population, and if a tumour were
composed only ofliving" tumour " cells, thenthe rate ofchange oftumour volume
and the potential growth rate ofits cells would give similar indices ofgrowth rate.
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This situation may hold for some small tumours, yet it is clear from evidence just
reviewed, that estimates ofhuman tumour volume doubling times tend to be much
longer than potential cell doubling times.
The rate ofchange oftumour volume may also dissociate from the actualgrowth
rate of its fertile cells. Dead cells, as well as living, non-fertile cells, continue to
occupy space and therefore contribute to tumour volume, at least for some time.
In a tumour mass with high rates of cell proliferation and of cell death, non-living
matter accumulates rapidly.
In normal steady state proliferating tissues, cell loss generally occurs at sites
anatomically distinct from the proliferation sites. For instance, blood cells are
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FIG. 1.-Hypothetical relationship between number of proliferative tumour cells and tumour
volume.
As the number of proliferative cells increases (A) tumour volume also increases. When
the number of proliferative cells is constant (B) new cell formation and cell corpses retained
in the mass continue to add to tumour volume. As the number of proliferative cells
decreases (C) tumour volume continues to increase until loss ofvolume from liquefaction and
phagocytosis exceed volume ofadded cells. Further reduction in proliferative cell numbers is
accompanied by reduction in volume (D). When no proliferative cells remain, tumour
continues to occupy a volume (E) which represents a " liquefaction lag ".
cannibalised in the reticulo-endothelial system and intestinal mucosal cells are shed
into the intestinal lumen. Tumours however are defective in the disposal ofdead
matter which accumulates near the site of cell proliferation. Whether tumour
volume increases, decreases, or remains constant, depends on the net balance
between the accretion and loss of all those elements which contribute to volume.
It follows that a reduction in the number of cells with proliferative potential in
a tumour mass, is not necessarily accompanied by a reduction in tumour volume,
although it is likely to be accompanied by a reduction in the rate of increase in
tumour volume. An analogy can be made with a fire where the total area of
devastation does not stop increasing until the fire is completely extinguished. But
the analogy is imperfect because liquefaction and phagocytic removal of debris
occur in tumours and at some point in the progressive reduction of a tumour cell
population, tumour volume tends to be stabilised, and a further reduction is the
number of proliferative cells is then associated with reduction in volume. The
hypothetical relationship is illustrated in Fig. 1. Examples ofthis dissociation are
to be seen in choriocarcinoma undergoing cytotoxic therapy. Tumours often
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continue to increase in size during the early stage of treatment. Later, when
volume is diminishing, the halving times ofthe cell population (as indicated by the
rate ofhormone production) have been only 2-10 days when the respective volume
halving times have been 30-60 days. Similarly, steady states of hormone excre-
tion have been associated with tumours which continue to increase in volume.
This suggests that tumour volume is only a poor guide to changes in the number of
fertile cells in a tumour mass. Since clinical assessment ofthe response oftumours
to therapy is largely based on observations oftumour volume, it is clear that it may
be erroneous to conclude that a therapeutic agent has been ineffective against the
proliferating cells ofatumour simply because tumourvolume has failed to decrease.
Action of anti-mitotic agents
The action ofanti-mitotic agents against proliferating cell populations can now
be considered. For this it is convenient to define two hypothetical agents, both of
which have the characteristic ofkilling cells as they prepare for mitosis during the
period of drug exposure, but which have no effect on cells which do not opt to
divide. They have ideal diffusion characteristics and reach the appropriate
receptor sites in all tumour cells in effective concentration. Cells do not become
resistant to their action either by adaptation or selection. They can be admini-
stered so that effective drug concentrations are attained immediately and sustained
for the period of administration, but their effects cease immediately they are dis-
continued. " A " is highly selective and kills only dividing tumour cells whereas
" B " is non-selective and does not discriminate between normal cells and tumour
cells. Thus "A " is non-toxic and can be administered for indefinite periods,
whereas " B" causes toxicity and can be allowed to act for only limited periods.
"A " can be regarded as the ultimate in mitotic agents and has no real counterpart;
"B " does not differ greatly from some existing agents and it may be compared
with an anti-metabolite such as the folic acid antagonist methotrexate.
Methotrexate inhibits DNA synthesis, and cells which enter S phase, that is the
phase of DNA replication (Howard and Pelc, 1953) during exposure to effective
concentrations of this drug, fail to produce viable daughter cells (Bertino, 1963;
Werkheiser, 1963, 1965). In its free form it is rapidly excreted and cells not
engaged in DNA synthesis during its administration appear to suffer no loss of
capacity to proliferate subsequently. For this reason, the fraction of cells in a
population killed by methotrexate approximates to the fraction entering S phase
during the period oftreatment and the size ofthis fraction is therefore a function of
the duration of treatment.
Since the duration ofS phase is short in comparison with the period ofaction of
hypothetical agent B in the present analysis, the number of cells which pass only a
part of S phase in a period of drug exposure is small enough to be ignored.
Fractional cell kill
There is some evidence that the fraction of the total number of fertile cells
which can be killed during a unit oftime tends to remain constant for a particular
population. Watson (1908) foundthatfor agiven concentration ofdisinfectantthe
time required to kill a bacterial population was a function ofthe initial size of the
population. His observations have often been confirmed (Pittillo et al., 1965;
Hunt and Pittillo, 1967).
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Studies of L 1210 murine leukaemia and of solid tumours (Skipper et al., 1964;
Wilcox et al., 1965) of Hodgkins disease (Johnson and Brace, 1966) and of chorio-
carcinoma (Bagshawe, 1968) have been consistent, with the conception that the
fraction of the tumour cell population which can be killed with antimitotic agents
during an interval oftime tends to remain constant over a wide range ofpopulation
size.
If susceptibility to an agent is dependent on cell division it is clear that the
potential rate at which a population can be destroyed (potential reduction rate) is
directly related to the potential growth rate. The killing of dividing cells means
that each mitosis results not in the addition ofa cell but in the loss ofa cell. Ifthe
fraction of surviving fertile cells which enter S phase in time t is constant
(dN/dt) k then the potential halving time is equal to the potential doubling
time (Fig. 2).
potential
growth
rate
potential
u) / , \ kill rate
0 z
0
ETREAT.MENT
TIME
FIG. 2.-Relationship between potential growth rate and potential kill rate for fast and slow
growing tumours exposed to effective anti-mitotic agent. The reciprocal relationship holds
because each mitosis results not in the addition, but in the loss ofa cell (luring exposure to the
agent.
Time required to eliminate a population of known size and potential doubling time in
the absence of spontaneous cell losses
The time required to eliminate a numerically defined tumour cell population
with hypothetical agent A can be calculated for various potential growth rates.
The time required to eliminate a moderate sized tumour population of 1010
(approx. 234) cells is indicated in Table II. The assumptions are that the rate of
entry of cells intc S phase is constant and unaltered by treatment and that no
spontaneous loss of cells occurs. Even for rapidly proliferating tumours the
duration of uninterrupted action required to eliminate the population is much
longer than the total duration of chemotherapy usually given in clinical practice.
For slowly proliferating tumours several years' continuous treatment would be
necessary.
Antimitotic agents which block DNA synthesis can be given continuously in
fully effective dosage for only about 4-5 days. To persist longer causes death; the
organism as a whole is more vulnerable than its most susceptible tissues. Hypo-
thetical agent B can therefore be proposed to kill all cells entering S phase ofthe cell
cycle during, say, a 4 day period which then has to be followed by a rest phase-
without treatment, to allow the recovery of normal tissues. Tumour growth is
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TABLE II.-Time Required to Eliminate a Tumour Cell Population of 1010
(approx. 234) As8uming a Constant Daily Fractional Kill
(1)
Tumour cell (2)
population Fractionoftumour (3)
halving time or cell population Number of days
doubling time eliminated required to reduce
(days) each day 1010 cells to < 100
0*5 . 075 . 17*5
1 . 0*5 . 35
2 . 0*25 . 70
5 . 0.1 . 175
10 . 0*05 . 350
20 . 0*025 . 700
50 . 0*01 . 1750
100 . 0*005 . 3500
resumed during the rest phase and the net effect of a complete treatment phase-
rest phase cycle is determined by the respective durations of the two phases, by
the loss of cells inflicted on normal and tumour populations, and by their respec-
tive rates ofrecovery.
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FIc. 3.-Effect of alternating treatment and rest phases ofequal duration on a proliferative cell
population from which there are no spontaneous cell losses. The population size would
remain constant.
Ifagent B were used in a therapeutic schedule in which the treatment and rest
phases were ofequal duration and if all the cells entering mitosis during the treat-
ment phase were killed but those entering mitosis during the rest phase divided
successfully, then the net effect ofthe whole cycle would be a steady state (Fig. 3).
In practice, an intensive 4 day course ofmethotrexate has to be followed by a rest
phase ofabout twice that duration. So that apopulation, exposed to a schedule of
4 days treatment followed by 8 days rest, would continue to grow, but at a slower
rate than if untreated (Fig. 4). If the potential doubling time of the population
were 4 days, then instead of increasing 8-fold in 12 days it would only increase
2-fold (Fig. 5). Thus an agent which is 100% efficient at killing mitosing cells
during the period of its action would fail to arrest growth; such a situation in
clinical practice would probably be interpreted as "drug resistance " since tumour
volume would continue to increase.
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Nor is there good reason to suppose that a combination of type B antimitotic
agents used simultaneously would prove more effective than a single agent. Iftwo
agents act only on cells in S phase or in mitosis their simultaneous use can only
effect an " overkill " of the same population. The combination of a type B anti-
mitotic with, say, an alkylating agent, would perhaps increase the number of cells
in
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FIG. 4. Effect of alternating treatment and rest phases with respective durations in the ratio
1: 2 on a proliferative cell population from which there are no spontaneous losses.
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FIG. 5.-Effect of4 day treatment and 8 day rest phases on a proliferative cell population with a
potential doubling time of4 days and no spontaneous losses. During the complete treatment-
rest cycle the population increases 2-fold when in the absence of treatment it would increase
8-fold.
in the tumour population sustaining lethal damage, but it could be expected
to exert a parallel effect on normal cell populations so that the rest phase would
have to be extended, and it does not follow that a net gain would necessarily be
achieved. There may, of course, be other valid reasons for using a combination of
cytotoxic agents, such as an attempt to achieve full blockade of DNA synthesis
where one agent alone is inadequate.
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Effect of spontaneous cell losses on effectiveness of anti-rn?totic agents
It is clearthat ifthe model so far constructed were representative ofalltumours,
then type B antimitotic agents would be incapable ofdoing more than reducing the
growth rate of any tumour, whereas in fact, agents such as methotrexate do elimi-
nate some human tumours when used cyclically in schedules similar to that just
described. If the foregoing analysis is correct this discrepancy can be attributed
only to spontaneous cell losses and these must now be incorporated into the
analvsis. It seems reasonable to assume that spontaneous losses occur during
both treatment and rest phases but it cannot be assumed that the rates of spon-
taneous loss are the same in the two phases. Since there is no firm basis for
computing the rates separately, it is convenient to group all spontaneous losses into
the rest phase and express them as a fraction of the total cells added by mitosis.
potential high
growth Cell los rats e ptntial 07reltiely
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FIG. 6. Effect of alternating treatment and rest phases with respective durations in the ratio
1 2 on a proliferative population from which (a) two thirds ofthe cells added by mitosis in the
rest phase are lost spontaneously; (b) more than two thirds of the added cells are lost
spontaneously.
When two-thirds of the cells added by mitosis during the rest phase are lost
spontaneously and the duration oftreatment and rest phases are in the ratio of 1 : 2
then the net effect of a complete treatment cycle with hypothetical agent B would
be a steady state (Fig. 6a). If spontaneous cell losses exceed two thirds of cells
added by mitosis in the rest phase then the population size would be reduced by the
amount of that excess (Fig. 6b). If cell losses were less than two thirds of the
added cells, the population would continue to show a net increase. Similar com-
putations can be made for other treatment-rest phase ratios.
Effect ofanti-mitotic agents on normal proliferating tissues
The duration of a course of antimitotic therapy is limited by the loss of ali-
mentary tract mucosal cells and the reduction of circulating leucocytes and plate-
lets. The patterns of cell proliferation in the intestinal crypts (Bizzozero, 1892;
Friedman, 1945; Leblond and Stevens, 1948; Fry et al., 1963) and the complexities
of haemopoiesis (Osgood, 1954; Cronkite et al., 1960; Lajtha et al., 1962; Patt and
Maloney, 1964) have been partially revealed. For the present purpose it is neces-
sary to adopt an over simplified model which distinguishes only between (i) a pre-
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cursor compartment which includes both fertile stem cells and the immediate
precursors of the tissue functional cells and (ii) the fully differentiated, non-
fertile, tissue functional cells.
By analogy with the analysis of the tumour population, cells are lost spon-
taneously from the precursor compartment into the differentiated compartment,
and in a steady state, losses equal 100% of the cells added by mitosis. The
spontaneous cell loss rate equals the potential growth rate and the potential kill
rate with an antimitotic also equals the potential growth rate. Combined spon-
taneous and therapy induced losses from a precursor compartment therefore
approach a limiting value equal to twice its potential growth rate.
This limiting rate would not be attained if therapy reduces the flux into the
differentiated compartment. It is a common observation that the peripheral
blood white cell and platelet counts do not usually fall until 3-4 days after starting
treatment with full doses ofan agent such as methotrexate, suggesting that normal
losses from the differentiated compartment continue to be made good by replace-
ments from the precursor compartment. It seems likely, therefore, that at least
for a substantial part ofa course oftreatment, cell losses bydifferentiation from the
precursor compartment are not greatly reduced and total losses may approach
the limiting rate.
It cannot be assumed that the potential growth rate of a normal steady state
population is its maximum growth rate. Cell production increases in response to
various stimuli and a reduction in the number of cells in the differentiated cell
compartment may be an appropriate direct or indirect stimulus to its respective
stem cell precursors. Ifthe number of cells preparing for mitosis increases during
a course of anti-mitotic therapy, then the therapy induced kill rate also increases.
During the early part of the rest phase an increased rate of proliferation in
normal precursor compartments aids rapid recovery from the losses incurred by
anti-mitotic action. During or following the reconstitution of stem cell popula-
tions, cells become available for differentiation and finally, as the normal number
of cells in the differentiated compartment is restored, so homeostatic mechanisms
may be supposed to operate so that stem cell proliferation is reduced to the rate
associated with the steady state.
Since some normal precursor compartments have higher potential kill rates and
greater spontaneous losses than expanding tumour populations, the combined
losses from these normal tissues are relatively greater than those from tumours
during a treatment phase. But when a complete cycle, consisting of a treatment
phase followed by a rest phase, does achieve a useful net effect (i.e. the fertile
tumour cell population fails to recover its initial size by the time normal dif-
ferentiated cell populations are fullyrestored), then it is clear that the advantage is
gained in the rest phase (Fig. 7). The duration of the rest phase is critical since
normal stem cell recovery is most rapid and outpaces the tumour cells in the early
part ofthe rest phase, but is later depressed to its steady state level by the opera-
tion ofhomeostatic mechanisms. Ifthe rest phase is unduly prolonged, the less is
the likelihood of a useful net effect, because the tumour population continues to
expand.
DISCUSSION
The general applicability ofanalyses ofthe present type depends on the degree
of dissociation between the conditions assumed and those which apply in reality.
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The validity ofthe model ofanti-mitotic action is clearly limited by the validity of
the model oftumour growth and it is recognised that it is not possible to encompass
processes of almost infinite complexity with a few highly simplified concepts.
It may also be argued that the validity ofthe present analysis is limited by the
adoption of hypothetical, rather than real, anti-mitotic substances. But the
present purpose is to attempt to define the potential value of agents whose action
is confined to killing cells in, or preparing for, mitosis. Although hypothetical
agent B, adopted for the analysis, corresponds to agents like methotrexate more
closely than to alkylating agents, vinca alkaloids or irradiation, it is suggested that
similar considerations probably apply to these agents also. Methotrexate is not
EXPANDIbG POPULATION STEADY STATEPOPLXATION
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FIG. 7.- Predicted effect-s of anti-mitotic action on an expanding tumour cell population and
on a normal steady state population (e.g. granulocytes and their precursors). The potential
growth rates andtherefore thepotential reduction ratesduringtherapyinthe twopopulations
are similar, but spontaneous losses are greater in the steady state population so that total
losses during the treatment phase are also greater. If the two populations recover their
initial size at the same time it is implicit that the steady state population has outpaced the
expanding population during theearly part ofthe rest phase before homeostatic mechanisms
effectively limit its own growth.
-* * *- Tumour cell population.
-Steady state-precursor population. ...... 6........ Steady state-differentiated cell population. PGR Potential growth rate.
AGR Actual growth rate.
SCLR Spontaneous cell loss rate.
notably more effective or less'effective than other anti-mitotic agents, but its mode
of action is such that the fraction of cells killed can be adequately defined on a
temporal basis, whereas the effects of many other agents are temporally dispersed
and less definable. Many notable studies of cell proliferation kinetics have been
based on radiobiology and it is unfortunate that the effects of irradiation are, in
this respect, less amenable to analysis than those of rapidly excreted anti-
metabolites. It is also clear that real agents cannot be more effective than the
hypothetical agents, except in so far as they possess a non-mitotic basis for a
selective effect.
It might be argued that susceptible human tumours are sensitive because of
certain intrinsic biochemical characteristics. If this were so, it might be anltici-
pated that such tumours would be susceptible to drug regimen which have no
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marked effect on normal cell proliferation. However, this does not appear to
occur. Nor is there clinical evidence of unusually prolonged drug action on
susceptible tumours, as might be expected ifthere were selective retention ofdrug
within their cells. Certain experimental tumours, it is true, have proved suscep-
tible only to certain cytotoxic agents and this would suggest that the effective
agents have an additional extra-mitotic action against these tumours; in either
event this is not relevant to the general thesis of anti-mitotic action.
That tumours respond well at first to anti-mitotics but later continue to grow
despite them is a frequent clinical sequence and it is usually attributed to the
operation of adaptive and selective mechanisms. It is not to be denied that these
mechanisms may indeed operate but the question is whether they usually account
for the apparent failure which follows a promising start. The fact that the
development ofresistance to one agent is frequently accompanied by resistance to
various other agents which act on different metabolic pathways (Hutchinson,
1963, 1965), seems to argue strongly against specific adaptive and selective
mechanisms, but is consistent with the hypothesis that non-sasceptibility to anti-
mitotics is dependent on proliferation kinetics which are unfavourable to anti-
mitotics in general.
The induction of resistance to methotrexate in bacterial and mammalian cells
has been readily achieved in vitro by convincingly selective mechanisms, but it was
only achieved with difficulty after several serial passages with the L 1210 mouse
leukaemia cell line in vivo (Welch, 1959). Increased dihydrofolate reductase levels
and impaired membrane transport ofmethotrexate found in mouse leukaemic cells
have been implicated as mechanisms of acquired resistance, but their relevance to
resistance by human tumour cells in vivo has not been established (Bertino, 1965;
Werkheiser, 1965).
Bertino (1965) observed that the development ofresistance by normal tissues to
methotrexate had not been seen, and in this unit patients receiving intensive
therapy for 2-3 years with methotrexate, 6-mercaptopurine, actinomycin-D and
other agents, have shown no loss ofsensitivity in their haemopoietic and mucosal
responses to these agents. Moreover, in patients where intensive chemotherapy
has failed to eliminate a choriocarcinoma, resistance by the tumour cell population
has not been absolute; tumour growth rates have invariably been lower during
chemotherapy than in rest periods. The tumours ofrelapsing patients frequently
show undiminished sensitivity to repeated treatment with the same agent (Fig. 8).
Choriocarcinoma, like Burkitt lymphoma, is sensitive to a wide range of cytotoxic
agents, although it is true that it is more sensitive to two particular agents.
On the present analysis, the emergence ofdrug resistance would be anticipated
on the basis of a reduced rate of spontaneous cell loss. There is no reason to
assume that this rate remains constant during substantial changes in tumour
volume. In large tumour masses the spontaneous cell death rate may be expected
to be high, asrecently demonstratedby Frindel et al. (1967), and thus a good initial
effect might be anticipated. Later, as a tumour's volume diminishes, spontaneous
losses may be so reduced that continued treatment does not result in a further
net reduction of the number of fertile cells. With continued treatment it would
be predicted that such a tumour would ultimately increase in volume but at a
slower rate than it would have done in the absence oftreatment. Alternatively, if
treatment is discontinued after a tumour has shown an initial reduction in volume
and is allowed to grow at its natural rate, back to its initial volume where spon-
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taneous losses again exceed the critical value, then further treatment at this time
would be expected to have an effect comparable to, but not necessarily as great as,
that achieved initially. Thus, where the spontaneous losses are readily depressed
below the critical value, drug resistance appears to occur, and the difference
achieved by frequently repeated courses of chemotherapy and by less frequently
repeated courses may be marginal. By contrast, where spontaneous losses remain
above the critical value, then further treatment can result in a further net reduc-
tion in the fertile tumour cells, but only provided the interval between successive
____Mothotrexate and
6-mercaptopurine
0~
6Iopoo.
0
b1000 x
100
0 3 6 9 12 15 18 '54 57
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FIG. 8.-Human chorionic gonadotrophin (HCG) excretion by a patient with choriocarcinoma
(Case No. 56). The patient relapsed following each of three series of treatments but has
remained inremissionfollowing alongerfourthseries oftreatments with the sameanti-mitotic
agents as used earlier. The rate oftumour destruction, as judged by the rate offall ofHCG
excretion, was similar with each series of treatments suggesting that failure to eliminate the
tumour with the earlier courses of treatment was not the result of adaptive or selective
mechanisms.
courses is kept to a minimum. Differences between palliative and potentially
curative chemotherapeutic regimen may therefore have some basis.
It would not be justified, however, to conclude that spontaneous cell losses are
always relatively greater the larger the tumour mass. These losses result from a
variety of mechanisms and the effect of treatment and change of volume on each
route of cell loss may differ substantially. Host response factors would be
expected to be most effective in causing tumour cell losses when the ratio of
tumour-host interface area to tumour volume is maximal, that is, when tumour
volume is minimal.
Except for tumours with a sustained high level of spontaneous cell death, the
present analysis provides no ground for supposing that cancer can be effectively
710TUMOUR GROWTH AND ANTI-MITOTIC ACTION
controlled with systemic anti-mitotic agents, however efficient, ifused alone. The
general toxic effects of anti-mitotics are often too high a price to pay for a slight
retardation ofgrowth. Butthis is not to saytheyhave noplace. It is nowwidely
recognised that factors which differentially stimulate the entry ofnormal or malig-
nant cells into mitosis, or differentially retard them, are potentially valuable.
It is also necessary to consider the possible contribution ofimmune mechanisms
to spontaneous cell losses and if possible to ensure that losses by this route are
augmented and not diminished bytherapy. There is aprimafacie casefor suppos-
ing that anti-mitotic agents might reduce the effectiveness of an immune reaction
to atumour, yet there is some evidence from choriocarcinoma thatthe contribution
from immune mechanisms is not necessarily obliterated by chemotherapy. Pre-
liminary evidence suggests that a marked mononuclear reaction to gestational
choriocarcinoma appears to be associated with abetter prognosis in chemotherapy-
treated patients than apoorreaction (Elston, 1968, unpublisheddata). Itisthere-
fore interesting that the agents used successfully in the treatment ofthis tumour,
methotrexate and actinomycin-D, have been observed to facilitate lymphocyte
interaction with target cells (Svet-Moldavsky et al., 1968).
The margin between success and failure in the chemotherapy of gestational
choriocarcinoma is often narrow and precarious, although in a majority ofpatients
it is fortunately possible to eliminate this tumour (Bagshawe, 1967; Hertz, 1967).
Despite the rather regular failure of anti-mitotic agents to eliminate most other
tumours, it would seem wrong to assume that the margin offailure is necessarily a
wide one. Thevalueofanti-mitotic action on manytumours maynotberealizable
until additional means ofkilling tumour cells become available.
SUMMARY
Changes in normal and malignant cell populations as a consequence of spon-
taneous and therapeutically induced cell losses have been analysed using a hypo-
thetical, fully effective, anti-mitotic agent, with a temporally defined period of
action, and compared with the effects of methotrexate on gestational chorio-
carcinoma.
Changes in the number of fertile tumour cells are not necessarily reflected by
changes of tumour volume.
The limiting rate at which an anti-mitotic agent can reduce a cell population is
equal to its potential growth rate. The potential reduction rates ofcertain normal
tissues are higher than those of most tumours.
In the absence ofspontaneous cell losses, an agent which is specifically lethal to
dividing tumour cells would need several years of continuous administration to
eliminate a moderate sized human tumour with a low potential growth rate; a non-
specific anti-mitotic agent could reduce, but not abolish, the rate of increase of a
tumour population, when used in maximum tolerated dosage.
The rates of spontaneous cell loss in normal proliferating steady state tissues
equal theirrespective potential growthrates andexceedthose inexpandingtumour
populations. Spontaneous losses in tumours occurby various routes and probably
change with size and other factors, within the same tumour.
When the spontaneous cell loss rate exceeds a value which is critical for each
therapeutic regimen, then anti-mitotic therapy can reduce tumour population size.
In those tumours which are eliminated by chemotherapy there is evidence ofhigh
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rates ofspontaneous cell loss. The higher the potential growth rate and the lower
the actual growth rate, the better the opportunity for anti-mitotic agents.
Total cell losses from certain normal proliferating tissues during anti-mitotic
therapy are relatively greater than from most tumours but, wheretherapy achieves
a useful net effect, normal tissue recovery outpaces tumour recovery until normal
tissue populations have been reconstituted.
I wish to thank Charing Cross Hospital Research Sub-committee for its support
and Dr. G. G. Steel, Dr. M. C. Pike, and Dr. B. M. Liversage for helpful discussions
on topics related to this paper.
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